The Biochemical Pharmacology Discussion Group
The New York Academy of Sciences
eBriefing 
Translational Approaches for Human Liver Disease
Reported by
Posted May 15, 2018
Presented By
Overview
Non-alcoholic steatohepatitis (NASH), a metabolic liver disorder characterized by fat deposition, inflammation, and insulin resistance, is the second leading cause of disease driving the need for liver transplantation in the United States. Currently, there are no approved treatments available. Scientists and clinicians have developed a better understanding of this disease state using animal models, targeted drugs, and risk alleles, but the development of human-translatable in vitro models of disease for drug metabolism and injury is still nascent, though data is growing. On February 20, 2018, the Biochemical Pharmacology Discussion Group at the New York Academy of Sciences presented Translational Approaches for Human Liver Diseases, a symposium on current and emerging in vitro model systems, covering potential benefits and limitations for the treatment of liver disease.
Speakers
Scott Friedman, MD, Icahn School of Medicine at Mount Sinai
Shyam Sundhar Bale, PhD, Draper Laboratory
Paulina Ordonez, MD, University of California, San Diego
Robert Schwartz, MD, PhD, Weill Cornell Medical College
Michael Shuler, PhD, Cornell University
Leah Norona, PhD, University of North Carolina, Chapel Hill
Ernesto Guccione, PhD, Icahn School of Medicine at Mount Sinai